Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
View ORCID ProfileLuis Rosero-Bixby
doi: https://doi.org/10.1101/2021.11.08.21266087
Luis Rosero-Bixby
Universidad de Costa Rica, Centro Centroamericano de Población (CCP)
Roles: Emeritus Professor
Data Availability
All data produced in the present work are contained in the manuscript (Appendix table)
Posted November 09, 2021.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
Luis Rosero-Bixby
medRxiv 2021.11.08.21266087; doi: https://doi.org/10.1101/2021.11.08.21266087
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2697)
- Dermatology (231)
- Emergency Medicine (406)
- Epidemiology (12336)
- Forensic Medicine (10)
- Gastroenterology (773)
- Genetic and Genomic Medicine (4179)
- Geriatric Medicine (393)
- Health Economics (689)
- Health Informatics (2704)
- Health Policy (1011)
- Hematology (366)
- HIV/AIDS (865)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3962)
- Nursing (216)
- Nutrition (587)
- Oncology (2090)
- Ophthalmology (597)
- Orthopedics (245)
- Otolaryngology (309)
- Pain Medicine (254)
- Palliative Medicine (76)
- Pathology (474)
- Pediatrics (1136)
- Primary Care Research (464)
- Public and Global Health (6596)
- Radiology and Imaging (1431)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (347)
- Surgery (458)
- Toxicology (56)
- Transplantation (192)
- Urology (170)